Format

Send to

Choose Destination
Cancer Discov. 2018 Jan;8(1):108-125. doi: 10.1158/2159-8290.CD-17-0532. Epub 2017 Sep 29.

Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
2
Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
3
Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. matthew_meyerson@dfci.harvard.edu.
5
Department of Pathology, Harvard Medical School, Boston, Massachusetts.

Abstract

The Krüppel-like family of transcription factors plays critical roles in human development and is associated with cancer pathogenesis. Krüppel-like factor 5 gene (KLF5) has been shown to promote cancer cell proliferation and tumorigenesis and to be genomically amplified in cancer cells. We recently reported that the KLF5 gene is also subject to other types of somatic coding and noncoding genomic alterations in diverse cancer types. Here, we show that these alterations activate KLF5 by three distinct mechanisms: (i) Focal amplification of superenhancers activates KLF5 expression in squamous cell carcinomas; (ii) Missense mutations disrupt KLF5-FBXW7 interactions to increase KLF5 protein stability in colorectal cancer; (iii) Cancer type-specific hotspot mutations within a zinc-finger DNA binding domain of KLF5 change its DNA binding specificity and reshape cellular transcription. Utilizing data from CRISPR/Cas9 gene knockout screening, we reveal that cancer cells with KLF5 overexpression are dependent on KLF5 for their proliferation, suggesting KLF5 as a putative therapeutic target.Significance: Our observations, together with previous studies that identified oncogenic properties of KLF5, establish the importance of KLF5 activation in human cancers, delineate the varied genomic mechanisms underlying this occurrence, and nominate KLF5 as a putative target for therapeutic intervention in cancer. Cancer Discov; 8(1); 108-25. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1.

PMID:
28963353
PMCID:
PMC5760289
[Available on 2019-01-01]
DOI:
10.1158/2159-8290.CD-17-0532

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center